Filings & corporate actions
73 results filed
CSVNext results · Q2 FY27
Expected 20 Oct 2026 – 29 Nov 2026
Estimate: filed 20–60 days after quarter end, last 5 times
2026
- 11 AugresultsResults · Q1 FY27 · standalone+3.3%NSE
- 17 JulshareholdingShareholding · 30 Jun 2026-3.2%NSE
- 29 MayresultsResults · Q4 FY26 · standalone-13.6%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026+0.8%NSE
- 5 FebresultsResults · Q3 FY26 · standalone-5.8%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-6.2%NSE
Reaction to results · all yearsrose on day 0 in 26 of 74 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 11 Aug 2026 | +3.3% | +6.0% | -3.8% | 4.7× |
| Q4 FY26 | 29 May 2026 | -13.6% | -18.2% | -9.0% | 7.7× |
| Q3 FY26 | 5 Feb 2026 | -5.8% | -2.2% | -5.9% | 0.9× |
| Q2 FY26 | 13 Nov 2025 | -3.4% | -7.8% | -4.7% | 1.3× |
| Q1 FY26 | 4 Aug 2025 | -2.4% | -7.0% | +2.0% | 2.3× |
| Q4 FY25 | 15 May 2025 | +9.8% | +3.6% | +12.5% | 17.6× |
| Q3 FY25 | 12 Feb 2025 | +1.6% | -6.7% | -7.9% | 2.9× |
| Q2 FY25 | 14 Nov 2024 | -4.0% | +0.4% | +39.6% | 0.8× |
| Q1 FY25 | 13 Aug 2024 | -2.9% | +13.6% | +34.6% | 1.2× |
| Q4 FY24 | 18 May 2024 | -5.0% | -10.1% | -2.8% | 5.6× |
| Q3 FY24 | 24 Jan 2024 | +0.2% | +6.0% | +11.5% | 3.3× |
| Q2 FY24 | 20 Oct 2023 | +2.0% | +3.9% | +4.5% | 3.3× |
| Q1 FY24 | 11 Aug 2023 | +2.0% | +8.0% | +17.2% | 0.3× |
| Q4 FY23 | 7 Jul 2023 | -3.6% | -11.5% | -11.5% | 1.9× |
| Q3 FY23 | 15 Feb 2023 | -4.0% | -8.7% | -21.6% | 0.9× |
| Q2 FY23 | 29 Nov 2022 | +3.5% | -2.3% | -9.5% | 1.3× |
| Q1 FY23 | 10 Aug 2022 | -5.0% | -14.4% | +0.5% | 1.1× |
| Q4 FY22 | 23 Jun 2022 | +4.9% | +8.9% | +7.4% | 0.1× |
| Q3 FY22 | 9 Feb 2022 | -5.0% | -15.9% | -25.9% | 0.5× |
| Q2 FY22 | 25 Nov 2021 | -3.2% | +7.2% | +11.0% | 0.9× |
| Q1 FY22 | 20 Oct 2021 | -3.3% | -16.5% | -11.0% | 0.9× |
| Q4 FY21 | 29 Jun 2021 | -5.0% | -9.7% | -8.7% | 0.4× |
| Q3 FY21 | 12 Feb 2021 | +5.0% | +26.0% | +28.0% | 2.9× |
| Q2 FY21 | 12 Nov 2020 | +0.4% | -0.1% | +19.2% | 1.5× |
| Q1 FY21 | 11 Sept 2020 | -4.6% | -4.0% | -5.5% | 1.3× |
| Q4 FY20 | 22 Jul 2020 | -4.9% | -13.4% | +32.7% | 4.3× |
| Q3 FY20 | 15 Feb 2020 | +4.8% | +32.8% | -14.9% | 31.4× |
| Q2 FY20 | 13 Nov 2019 | +4.9% | +32.6% | +47.3% | 2.4× |
| Q1 FY20 | 14 Aug 2019 | -4.2% | -8.3% | -8.0% | 1.9× |
| Q4 FY19 | 14 Aug 2019 | -4.2% | -8.3% | -8.0% | 1.9× |
| Q3 FY19 | 1 Mar 2019 | +4.3% | +11.6% | +26.9% | 1.0× |
| Q2 FY19 | 22 Nov 2018 | -4.0% | +4.0% | -5.5% | 0.4× |
| Q4 FY18 | 30 Aug 2018 | -1.8% | +5.2% | -16.7% | 0.7× |
| Q1 FY19 | 30 Aug 2018 | -1.8% | +5.2% | -16.7% | 0.7× |
| Q3 FY18 | 15 Feb 2018 | -1.6% | -2.5% | -12.1% | 1.1× |
| Q2 FY18 | 12 Dec 2017 | +4.9% | +4.7% | +22.0% | 4.0× |
| Q1 FY18 | 13 Sept 2017 | -1.8% | -2.6% | -3.6% | 3.2× |
| Q4 FY17 | 17 Jun 2017 | -3.3% | -2.9% | +2.6% | 0.5× |
| Q3 FY17 | 15 Feb 2017 | -4.9% | -7.4% | -20.0% | 0.1× |
| Q2 FY17 | 2 Dec 2016 | +4.9% | +33.5% | +41.4% | 0.4× |
| Q1 FY17 | 13 Aug 2016 | -4.9% | -13.6% | -8.4% | 0.1× |
| Q4 FY16 | 19 May 2016 | -3.2% | -10.3% | -8.0% | 0.8× |
| Q3 FY16 | 13 Feb 2016 | -4.9% | -16.1% | -5.8% | 1.9× |
| Q2 FY16 | 7 Nov 2015 | -2.5% | -5.8% | -2.5% | 2.5× |
| Q1 FY16 | 16 Aug 2015 | +3.3% | -10.0% | -15.8% | 1.6× |
| Q4 FY15 | 22 May 2015 | -5.0% | -18.7% | -3.4% | 0.2× |
| Q3 FY15 | 19 Feb 2015 | +4.9% | +19.0% | +74.3% | 0.5× |
| Q4 FY14 | 16 May 2014 | +2.5% | +11.6% | +28.2% | 2.8× |
| Q3 FY14 | 26 Feb 2014 | -1.3% | +2.7% | -4.2% | 0.5× |
| Q2 FY14 | 22 Nov 2013 | -3.0% | +1.1% | +0.8% | 0.7× |
| Q1 FY14 | 16 Aug 2013 | -6.6% | -8.9% | -0.5% | 0.9× |
| Q4 FY13 | 12 Jun 2013 | 0.0% | -3.2% | -0.2% | 0.1× |
| Q3 FY13 | 11 Feb 2013 | -3.9% | -12.8% | -5.5% | 0.3× |
| Q2 FY13 | 5 Nov 2012 | -2.7% | -4.4% | +2.9% | 0.2× |
| Q1 FY13 | 6 Aug 2012 | 0.0% | +4.4% | -8.3% | 1.1× |
| Q4 FY12 | 29 May 2012 | +1.5% | -5.5% | +2.6% | 0.2× |
| Q3 FY12 | 10 Feb 2012 | -9.2% | -14.1% | -25.6% | 1.5× |
| Q2 FY12 | 8 Nov 2011 | +0.2% | -13.2% | -7.7% | 4.1× |
| Q1 FY12 | 18 Aug 2011 | -1.6% | -4.7% | +8.1% | 1.1× |
| Q4 FY11 | 7 Jun 2011 | -1.7% | -4.4% | -10.2% | 0.1× |
| Q3 FY11 | 2 Feb 2011 | -10.7% | -29.4% | -24.7% | 3.0× |
| Q2 FY11 | 29 Oct 2010 | -5.6% | -6.3% | -32.8% | 1.3× |
| Q1 FY11 | 12 Aug 2010 | -3.8% | -4.7% | -2.4% | 3.9× |
| Q4 FY10 | 28 May 2010 | +15.4% | +11.1% | +20.9% | 6.0× |
| Q3 FY10 | 22 Jan 2010 | -2.6% | -1.3% | -6.7% | 0.7× |
| Q2 FY10 | 28 Oct 2009 | -5.0% | -23.0% | -13.2% | 0.5× |
| Q1 FY10 | 27 Jul 2009 | +19.3% | +35.9% | +53.1% | 5.8× |
| Q4 FY09 | 30 Jun 2009 | -3.4% | -10.8% | +11.4% | 0.3× |
| Q3 FY09 | 30 Jan 2009 | -2.2% | -0.3% | -10.5% | 0.2× |
| Q4 FY08 | 27 Jun 2008 | +0.6% | +2.8% | +2.3% | 0.4× |
| Q3 FY08 | 30 Jan 2008 | +2.5% | +12.9% | +0.8% | 0.4× |
| Q2 FY08 | 31 Oct 2007 | -0.2% | -2.5% | -4.5% | 1.5× |
| Q1 FY08 | 30 Jul 2007 | +0.2% | +6.8% | -0.4% | 0.1× |
| Q4 FY07 | 29 Jun 2007 | +14.9% | +10.3% | +10.0% | 26.0× |
| Average | -0.9% | -1.0% | +1.9% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY26
CSVRevenue YoY+1.5%
Profit YoY-76.0%
Interest cost YoY-17.6%
Revenue QoQ+0.6%
Profit QoQ-85.1%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +7.9% | +7.3% | +6.9% | +7.6% | +11.5% | +7.3% |
| Profit | +44.5% | +231.3% | -7.1% | — | — | — |
Key data
CSVOpen194.99
Day range191.15 – 205.81
52-week range161.50 – 358.85
From 52w high-44.9%
RSI (14)29.5
ATR (14)12.65
Volume11.43L
Avg volume (20D)2.73L
Rel volume4.19×
Volatility (1Y)53.7%
Turnover₹22.6Cr
SMA 50 / 200250.34 / 253.92
Delivery percentage
Latest · 6 Oct 202652.4%
20-day avg47.6%
1-year avg64.6%
Percentile (own history)8th
Range14.1–100.0%
Sessions1,711
Over the last 20 sessions WANBURY settled 47.6% of its traded quantity, which is above average for an NSE equity. Its one-year average is 64.6%, so recent sessions are running 16.9 points lower than usual. The latest session ranks higher than 8% of the 1,711 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +3.89% | -10.97% | -18.69% | -29.04% | -14.12% | -19.74% |
Valuation
CSVMarket cap₹692 Cr
P/E (TTM)12.4
EPS (TTM)15.98
Shares outstanding3.29Cr
Listed29 Jan 2007
Ownership
CSVPromoter43.02%
Promoter Δ QoQ0.00 pp
Public56.98%
FII0.89%
DII0.06%
Pledged86.69%
Quarterly results · consolidated
CSV| Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 161.2 | 133.5 | 172.0 | 163.2 |
| YoY chg | +11.6% | -8.3% | +23.4% | +24.5% |
| Net profit (₹ Cr) | 8.0 | 1.2 | 20.3 | 13.5 |
| YoY chg | +8.9% | -88.1% | -39.8% | +1200.4% |
| Net margin | 5.0% | 0.9% | 11.8% | 8.3% |
| EPS | 2.34 | 0.70 | 5.98 | 3.95 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 43.02% · public 56.98%2021-092026-06
- Promoter
- Public and others
- Promoter
- 43.02%
- Public
- 56.98%
- Promoter change
- 0.00 pp
- Filed
- 17 Jul 2026
- FII
- 0.89%
- DII
- 0.06%
- Promoter pledged
- 86.69%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY23 | Q3 FY23 | Q4 FY23A | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 124.0 | 125.8 | 133.0 | 146.3 | 144.5 | 145.5 | 139.4 | 131.1 | 161.2 | 133.5 | 172.0 | 163.2 | |
| Other income | 0.8 | 0.3 | (2.1) | 0.6 | 0.8 | 0.7 | 0.9 | 0.9 | 1.6 | 0.8 | 1.8 | 0.3 | |
| Total income | 124.7 | 126.0 | 130.9 | 146.9 | 145.2 | 146.2 | 140.3 | 132.1 | 162.8 | 134.3 | 173.8 | 163.5 | |
| Total expenses | 125.4 | 129.1 | 129.4 | 141.9 | 138.0 | 135.9 | 132.0 | 131.0 | 154.7 | 133.0 | 154.8 | 149.9 | |
| └ Finance costs | 3.9 | 6.6 | 7.5 | 5.8 | 7.7 | 8.3 | 7.5 | 7.6 | 10.1 | 10.2 | 9.0 | 7.5 | |
| └ Depreciation | 3.2 | 3.1 | 3.1 | 3.2 | 3.2 | 3.3 | 3.3 | 3.3 | 3.3 | 3.3 | 3.4 | 3.6 | |
| Profit before tax | (0.7) | (3.0) | 0.9 | 5.0 | 7.2 | 10.3 | 33.9 | 1.0 | 8.2 | 1.3 | 19.1 | 13.6 | |
| Tax expense | 0.2 | 0.2 | (0.1) | 0.3 | (0.2) | (0.0) | 0.3 | 0.0 | 0.1 | 0.1 | (1.2) | 0.1 | |
| Net profit | (0.9) | (3.3) | 1.0 | 4.7 | 7.4 | 10.3 | 33.6 | 1.0 | 8.0 | 1.2 | 20.3 | 13.5 | |
| EPS | -0.27 | -1.00 | 0.80 | 1.43 | 2.25 | 3.13 | 12.75 | 0.32 | 2.44 | 0.76 | 6.18 | 4.12 | |
| Net margin | -0.72% | -2.61% | 0.76% | 3.20% | 5.10% | 7.06% | 24.13% | 0.79% | 4.97% | 0.91% | 11.78% | 8.27% | |
| PBT margin | -0.57% | -2.42% | 0.69% | 3.41% | 4.97% | 7.05% | 24.32% | 0.79% | 5.07% | 0.97% | 11.08% | 8.34% | |
| Tax rate | — | — | -10.34% | 6.06% | -2.45% | -0.17% | 0.80% | 0.00% | 1.82% | 5.76% | -6.31% | 0.85% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 4 Aug 2025.
WANBURY at a glance
- WANBURY closed at ₹197.87 on 6 Oct 2026, +3.89% on the day, -19.7% over one year, 44.9% below its 52-week high of ₹358.85.
- Delivery was 52.4% of traded quantity on 6 Oct 2026, the 8th percentile of its own 1,711 sessions with a reading (20-session average 47.6%, 1-year average 64.6%).
- Market capitalisation is ₹692 crore at a trailing P/E of 12.4 (trailing EPS ₹15.98).
- Q1 FY26 results (consolidated, filed 4 Aug 2025): revenue ₹163 crore (+24.5% year on year), net profit ₹13 crore (+1200.4%); the price moved -2.4% on the first session after.
- Promoters held 43.02% at 30 Jun 2026, unchanged on the previous filing, with 86.69% of promoter shares pledged.
- Q2 FY27 results are expected between 20 Oct 2026 and 29 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE107F01022
SeriesEQ
Listed29 Jan 2007
History from29 Jan 2007
Sessions4,870
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE